Historical records report the use of cannabis for pain treatment around 3000 BC. However, only in the 1960s, the active components of cannabis (CBD, THC, and 100 others) were described by scientists, and finally, in 1980, the first endogenous cannabinoid, anandamide (AEA), was identified, which reiterated the significance of the cannabinoid receptor and its endogenous ligands in controlling a wide variety of biological activities. The Sanskrit name “anandamide” (“ananda” = happiness) is given to N-araquidonoyl ethanolamine, for its cannabinoid-mimetic effects. Subsequently, another endogenous cannabinoid compound, known as 2-araquidonoilglycerol (2-AG), was identified. Considering that these compounds are endogenous and cannabinomimetic, acting at cannabinoid receptors, they have been termed endocannabinoids (EC), which, along with synthesis and degradation enzymes, make up the Endocannabinoid System (ECS). Nowadays, among the therapeutic options that aim at a better quality of life for patients, the use of cannabinoids as an adjuvant in treatment has gained great prominence in scientific studies that show its therapeutic potential in acute and chronic pain.

About the author : Reinaldo Souza

Leave A Comment

Related posts

Popular products

Product categories